Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

Ikeda M.; Shimizu S.; Sato T.; Morimoto M.; Kojima Y.; Inaba Y.; Hagihara A.; Kudo M.; Nakamori S.; Kaneko S.; Sugimoto R.; Tahara T.; Ohmura T.; Yasui K.; Sato K.; Ishii H.; Furuse J.; Okusaka T.

首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

【24h】

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

机译：索拉非尼联合顺铂与索拉非尼联合肝动脉灌注化疗治疗晚期肝细胞癌：II期随机试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Sorafenib (Sor) is acknowledged as a standard therapy for advanced hepatocellular carcinoma (HCC). This trial was conducted to evaluate the effect of addition of hepatic arterial infusion chemotherapy with cisplatin (SorCDDP) to Sor for the treatment of advanced HCC.

机译：索拉非尼（Sor）被认为是晚期肝细胞癌（HCC）的标准疗法。进行该试验以评估在Sor中加入顺铂（SorCDDP）肝动脉灌注化疗对晚期HCC的治疗效果。

著录项

来源
《Annals of oncology: official journal of the European Society for Medical Oncology》 |2016年第11期|共7页
作者
Ikeda M.; Shimizu S.; Sato T.; Morimoto M.; Kojima Y.; Inaba Y.; Hagihara A.; Kudo M.; Nakamori S.; Kaneko S.; Sugimoto R.; Tahara T.; Ohmura T.; Yasui K.; Sato K.; Ishii H.; Furuse J.; Okusaka T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
cisplatin; hepatic arterial infusion chemotherapy; hepatocellular carcinoma; sorafenib; randomized phase II trial;

机译：顺铂;肝动脉灌注化疗;肝细胞癌;索拉非尼;II期随机试验;

相似文献

外文文献
中文文献
专利

1. Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al. [J] . Ikeda M., Shimizu S., Sato T., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第4期

机译：回复致编辑的索拉非尼布加肝动脉输液化疗与顺铂与索拉非尼治疗的先进肝细胞癌：随机期II试验'，由Fornaro等。
2. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial [J] . Ikeda M., Shimizu S., Sato T., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第11期

机译：索拉非尼联合顺铂与索拉非尼联合肝动脉灌注化疗治疗晚期肝细胞癌：II期随机试验
3. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial [J] . Masahiro Hatooka, Tomokazu Kawaoka, Hiroshi Aikata, BMC Cancer . 2018,第1期

机译：晚期肝细胞癌（HICS 55）患者的肝动脉灌注化疗后加索拉非尼：一项开放性，非对照，II期临床研究
4. Molecular Therapies in Hepatocellular Carcinoma beyond Sorafenib: Lessons from Failed Phase III Trials and Novel Targets [C] . Lipika Goyal, Andrew X. Zhu Gastrointestinal Cancers Symposium . 2014

机译：Sorafenib之外的肝细胞癌中的分子疗法：III期试验失败的课程和新型靶标
5. Poly(lactide-co-glycolide) Microspheres for Localized, Magnetic Resonance Imaging Monitored, Transcatheter Delivery of Sorafenib to Hepatocellular Carcinoma. [D] . Chen, Jeane. 2015

机译：聚（丙交酯-共-乙交酯）微球体用于局部监测，磁共振成像监测，索拉非尼经导管输送至肝细胞癌。
6. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial [O] . M. Ikeda, S. Shimizu, T. Sato, -1

机译：索拉非尼联合肝动脉灌注化疗联合顺铂与索拉非尼治疗晚期肝细胞癌：II期随机试验
7. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial [O] . Masaaki Kondo, Manabu Morimoto, Satoshi Kobayashi, 2019

机译：随机，序贯肝动脉输注化疗和索拉非尼试验的II次试验单独作为先进肝细胞癌的初始治疗：SCOOP-2试验

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

摘要

著录项

相似文献

相关主题

期刊订阅